- Foghorn Therapeutics Inc. (FHTX) reported **$198.7 million in cash and equivalents** as of **June 30, 2025**, providing a cash runway into **2028**.  **[1822462_0001822462-25-000007_a2025-09x02foghorncorpor.htm:2]** 
- The company's strategic collaboration with **Lilly**, established in **December 2021**, included **$380 million upfront** and a **50/50 U.S. economic split** on two lead programs, one of which is **FHD-909**.  **[1822462_0001822462-25-000007_a2025-09x02foghorncorpor.htm:2]** 
- **FHD-909**, a Selective SMARCA2 Inhibitor, is currently in a **Phase 1 monotherapy dose escalation trial**, initiated by Lilly in **2024**.  **[1822462_0001822462-25-000007_a2025-09x02foghorncorpor.htm:2]** **[1822462_0001822462-25-000007_a2025-09x02foghorncorpor.htm:3]** 
- Foghorn is also advancing multiple preclinical assets, such as Selective CBP Degrader and Selective EP300 Degrader, with **IND/Phase 1 initiation planned for 2026**.  **[1822462_0001822462-25-000007_a2025-09x02foghorncorpor.htm:2]** **[1822462_0001822462-25-000007_a2025-09x02foghorncorpor.htm:10]**

Foghorn Therapeutics (FHTX)